All In Biotech

NDA 020118 · Baxter Hlthcare

Suprane

Desflurane · Inhalation · General Anesthetic

Novel

Last checked: Nov 19, 2026Latest source record: Nov 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Sep 18, 1992

Approved uses

2

Original approval plus efficacy supplements

Registered trials

221

12 Phase 3, 12 recruiting

FAERS reports

1,717

1,636 serious, 112 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 15, 2026.

1. INDICATIONS AND USAGE 1.1 Induction of Anesthesia SUPRANE is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. SUPRANE is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. 1.2 Maintenance of Anesthesia SUPRANE is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. After induction of anesthesia with agents other than SUPRANE, and tracheal intubation, SUPRANE is indicated for maintenance of anesthesia in infants and children. SUPRANE is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [See WARNINGS AND PRECAUTIONS (5.3) and CLINICAL STUDIES (14.5)]. Suprane is an inhalation agent indicated: for induction and/or maintenance of anesthesia in adults (1.1) for maintenance of anesthesia in pediatric patients following induction with agents other than Suprane and intubation.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SUPRANE · DESFLURANE 100% · LIQUID, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Desflurane" as an intervention, any sponsor and status, largest first.

All 221 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension119
  • bradycardia103
  • cardiac arrest99
  • drug interaction97
  • anaphylactic shock93
  • serotonin syndrome74
  • hyperthermia malignant64
  • anaphylactic reaction59
  • bronchospasm58
  • drug ineffective58
  • tachycardia57
  • foetal exposure during pregnancy48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200537
200636
200730
200857
200955
201068
201166
201295
2013118
2014105
2015120
2016108
2017116
2018138
2019114
202084
202176
202261
202365
202464
202546
202637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 861 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.